With the recent development of various new treatments, April Armstrong, MD, MPH, discusses the new standards she and other dermatologists hope to set for treating patients with atopic dermatitis (AD).
April Armstrong, MD, MPH, professor and chief of dermatology at the University of California, Los Angeles, discusses the new standards she and other dermatologists hope to set with the recent emergence of various new and improved atopic dermatitis (AD) treatment developments.
Transcript
Since so many new and improved treatments have recently been developed, what is the "new standard" you hope to set for treating patients with atopic dermatitis?
When we think about new standards for the treatment of patients with atopic dermatitis, I think it's very important to establish treatment goals. Treatment goals are something, for example, in the psoriasis field, we have had for a while, and it's relatively more mature than other areas of inflammatory skin disease.
I think having treatment goals and having these new standards really forces us to think about where we can get our patients, and it almost pushes us to make sure that, when we see each patient in front of us, we have an established goal in our mind for the patient and the patient also knows that we are working together in concert toward that common goal. I think without that either the patient or we may be complacent at a stage where the patient's really not optimally managed, and the patient may not even know what is possible.
I think, as a community, we are looking at what those goals should be, and there have been several proposals that have been made around what that should be. I think, overall, we are trying to find our footing in terms of defining the treatment goals, and then, importantly, how to convince our colleagues to achieve these treatment goals so that we are really working together, methodically and strategically, to make sure that we are monitoring the patient progress and using appropriate therapy to get them to the goal as quickly as possible.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More